Adam Kashishian

3.6k total citations · 1 hit paper
32 papers, 2.9k citations indexed

About

Adam Kashishian is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Adam Kashishian has authored 32 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 13 papers in Genetics and 12 papers in Oncology. Recurrent topics in Adam Kashishian's work include PI3K/AKT/mTOR signaling in cancer (22 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Protein Kinase Regulation and GTPase Signaling (11 papers). Adam Kashishian is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (22 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Protein Kinase Regulation and GTPase Signaling (11 papers). Adam Kashishian collaborates with scholars based in United States, Germany and South Africa. Adam Kashishian's co-authors include Jonathan A. Cooper, Andrius Kazlauskas, Riko Nishimura, Joseph Schlessinger, Brian J. Lannutti, Sarah Meadows, Mindaugas Valius, Andreas Batzer, Wei Li and Bart Steiner and has published in prestigious journals such as Journal of Biological Chemistry, The EMBO Journal and Blood.

In The Last Decade

Adam Kashishian

32 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

2010 588 citations Brian J. Lannutti, Sarah Meadows et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adam Kashishian United States	19	2.2k	769	687	664	399	32	2.9k
Mikhail L. Gishizky United States	20	1.7k 0.8×	717 0.9×	284 0.4×	446 0.7×	203 0.5×	30	3.0k
Marina Holgado-Madruga United States	24	2.4k 1.1×	1.1k 1.4×	534 0.8×	250 0.4×	187 0.5×	33	3.3k
Neill A. Giese United States	26	2.2k 1.0×	650 0.8×	741 1.1×	1.8k 2.6×	920 2.3×	43	4.5k
Mark A. Pershouse United States	15	2.4k 1.1×	615 0.8×	289 0.4×	434 0.7×	433 1.1×	33	3.1k
Michelle Kuhne United States	14	933 0.4×	788 1.0×	1.1k 1.5×	243 0.4×	177 0.4×	35	2.2k
Chiara Ambrogio United States	29	1.8k 0.8×	988 1.3×	416 0.6×	176 0.3×	619 1.6×	73	3.0k
Ingo Ringshausen Germany	21	1.0k 0.5×	739 1.0×	335 0.5×	611 0.9×	387 1.0×	47	1.8k
Huai Lin United States	8	2.3k 1.0×	576 0.7×	243 0.4×	465 0.7×	437 1.1×	9	2.7k
Diana Linnekin United States	23	839 0.4×	532 0.7×	935 1.4×	377 0.6×	96 0.2×	40	2.0k
Luca Mologni Italy	32	1.7k 0.8×	942 1.2×	225 0.3×	784 1.2×	403 1.0×	91	3.4k

Countries citing papers authored by Adam Kashishian

Since Specialization

Citations

This map shows the geographic impact of Adam Kashishian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Kashishian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Kashishian more than expected).

Fields of papers citing papers by Adam Kashishian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Kashishian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Kashishian. The network helps show where Adam Kashishian may publish in the future.

Co-authorship network of co-authors of Adam Kashishian

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Kashishian. A scholar is included among the top collaborators of Adam Kashishian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Kashishian. Adam Kashishian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Ting, Karen Schwartz, Peidong Fan, et al.. (2020). Direct Measurement of the Intracellular Concentration of 8-Oxo-2'-Deoxyguanosine-5'-Triphosphate by LC-MS/MS. Journal of Bioanalysis & Biomedicine. 12(6). 1–8. 1 indexed citations

Perreault, Stéphane, Jayaraman Chandrasekhar, Zhi-Hua Cui, et al.. (2017). Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856. Journal of Medicinal Chemistry. 60(4). 1555–1567. 27 indexed citations

Sorensen, Rick, Sarah Meadows, Li Li, et al.. (2015). Investigation of the Mechanism of Idelalisib Resistance in the Follicular Lymphoma WSU-Fsccl Cell Line. Blood. 126(23). 2482–2482. 4 indexed citations

Tanabe, Natsuko, Adam Kashishian, Bart Steiner, et al.. (2013). Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts. Journal of Biological Chemistry. 288(49). 35346–35357. 36 indexed citations

Subramaniam, Prem S., Valeria Tosello, Kim De Keersmaecker, et al.. (2012). Targeting Nonclassical Oncogenes for Therapy in T-ALL. Cancer Cell. 21(4). 459–472. 69 indexed citations

Kashishian, Adam, Sarah Meadows, Bart Steiner, & Brian J. Lannutti. (2011). Abstract 3555: Anti-tumor activity of CAL-101, a potent selective inhibitor of the p110Δ isoform of PI3K, in models of human glioblastoma. Cancer Research. 71(8_Supplement). 3555–3555. 1 indexed citations

Meadows, Sarah, Adam Kashishian, Dave Johnson, Volker Diehl, & Brian J. Lannutti. (2010). CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma. Blood. 116(21). 3926–3926. 13 indexed citations

Lannutti, Brian J., Sarah Meadows, Sarah E.M. Herman, et al.. (2010). CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 117(2). 591–594. 588 indexed citations breakdown →

Lannutti, Brian J., Sarah Meadows, Adam Kashishian, et al.. (2009). CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment.. Blood. 114(22). 286–286. 6 indexed citations

10.

May, Sarah, Adam Kashishian, Thomas S. Lin, et al.. (2008). CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease. Blood. 112(11). 3165–3165. 4 indexed citations

11.

Kashishian, Adam, Monique Howard, Christine Loh, et al.. (1998). AKAP79 Inhibits Calcineurin through a Site Distinct from the Immunophilin-binding Region. Journal of Biological Chemistry. 273(42). 27412–27419. 76 indexed citations

12.

Chantry, David, Anne B. Vojtek, Adam Kashishian, et al.. (1997). p110δ, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in Leukocytes. Journal of Biological Chemistry. 272(31). 19236–19241. 210 indexed citations

13.

Li, Wei, Riko Nishimura, Adam Kashishian, et al.. (1994). A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Molecular and Cellular Biology. 14(1). 509–517. 415 indexed citations

14.

Cooper, Jonathan A. & Adam Kashishian. (1993). In Vivo Binding Properties of SH2 Domains from GTPase-Activating Protein and Phosphatidylinositol 3-Kinase. Molecular and Cellular Biology. 13(3). 1737–1745. 18 indexed citations

15.

Kashishian, Adam & Jonathan A. Cooper. (1993). Phosphorylation sites at the C-terminus of the platelet-derived growth factor receptor bind phospholipase C gamma 1.. Molecular Biology of the Cell. 4(1). 49–57. 64 indexed citations

16.

Nishimura, Riko, W Li, Adam Kashishian, et al.. (1993). Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor. Molecular and Cellular Biology. 13(11). 6889–6896. 38 indexed citations

17.

Cooper, Jonathan A. & Adam Kashishian. (1993). In vivo binding properties of SH2 domains from GTPase-activating protein and phosphatidylinositol 3-kinase.. Molecular and Cellular Biology. 13(3). 1737–1745. 59 indexed citations

18.

Nishimura, Riko, W Li, Adam Kashishian, et al.. (1993). Two signaling molecules share a phosphotyrosine-containing binding site in the platelet-derived growth factor receptor.. Molecular and Cellular Biology. 13(11). 6889–6896. 165 indexed citations

19.

Kazlauskas, Andrius, Adam Kashishian, Jonathan A. Cooper, & Mindaugas Valius. (1992). GTPase-Activating Protein and Phosphatidylinositol 3-Kinase Bind to Distinct Regions of the Platelet-Derived Growth Factor Receptor β Subunit. Molecular and Cellular Biology. 12(6). 2534–2544. 36 indexed citations

20.

Kashishian, Adam, Andrius Kazlauskas, & Jonathan A. Cooper. (1992). Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo.. The EMBO Journal. 11(4). 1373–1382. 282 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact